{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:10:42Z","timestamp":1792289442146,"version":"4.4.0"},"reference-count":38,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"unspecified","delay-in-days":153,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["QRB Discovery"],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study presents the background, rationale and method of action of Biovacc-19, a candidate vaccine for corona virus disease 2019 (Covid-19), now in advanced preclinical development, which has already passed the first acute toxicity testing. Unlike conventionally developed vaccines, Biovacc-19\u2019s method of operation is upon nonhuman-like (NHL) epitopes in 21.6% of the composition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\u2019s spike protein, which displays distinct distributed charge including the presence of a charged furin-like cleavage site. The logic of the design of the vaccine is explained, which starts with empirical analysis of the aetiology of SARS-CoV-2. Mistaken assumptions about SARS-CoV-2\u2019s aetiology risk creating ineffective or actively harmful vaccines, including the risk of antibody-dependent enhancement. Such problems in vaccine design are illustrated from past experience in the human immunodeficiency viruses domain. We propose that the dual effect general method of action of this chimeric virus\u2019s spike, including receptor binding domain, includes membrane components other than the angiotensin-converting enzyme 2 receptor, which explains clinical evidence of its infectivity and pathogenicity. We show the nonreceptor dependent phagocytic general method of action to be specifically related to cumulative charge from insertions placed on the SARS-CoV-2 spike surface in positions to bind efficiently by salt bridge formations; and from blasting the spike we display the NHL epitopes from which Biovacc-19 has been down-selected.<\/jats:p>","DOI":"10.1017\/qrd.2020.8","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T02:54:01Z","timestamp":1591066441000},"source":"Crossref","is-referenced-by-count":18,"title":["Biovacc-19: A Candidate Vaccine for Covid-19 (SARS-CoV-2) Developed from Analysis of its General Method of Action for Infectivity"],"prefix":"10.1017","volume":"1","author":[{"given":"Birger","family":"S\u00f8rensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Susrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus George","family":"Dalgleish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"S2633289220000083_r35","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-015-0571-8"},{"key":"S2633289220000083_r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2019.100141"},{"key":"S2633289220000083_r26","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(00)02072-X"},{"key":"S2633289220000083_r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.01.025"},{"key":"S2633289220000083_r30","unstructured":"Uniprot \u2013 Q9BYF1. Angiotensin-Converting Enzyme 2. Available at https:\/\/www.uniprot.org\/uniprot\/Q9BYF1 (accessed 02 August 2005)."},{"key":"S2633289220000083_r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2011.07.001"},{"key":"S2633289220000083_r3","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-01221-y"},{"key":"S2633289220000083_r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.11.003"},{"key":"S2633289220000083_r19","first-page":"w20249","article-title":"Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?","volume":"150","author":"Negro","year":"2020","journal-title":"Swiss Medical Weekly"},{"key":"S2633289220000083_r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.09.028"},{"key":"S2633289220000083_r28","unstructured":"Uniprot \u2013 P0DTC2. Spike Glycoprotein, Human SARS Coronavirus 2 (SARS-CoV-2). Available at https:\/\/www.uniprot.org\/uniprot\/P0DTC2 (accessed 22 April 2020)."},{"key":"S2633289220000083_r31","unstructured":"Uniprot \u2013 Q9N2X3. C-Type Lectin Domain Family 4 Member M. Available at https:\/\/www.uniprot.org\/uniprot\/Q9H2X3 (accessed 01 October 2000)."},{"key":"S2633289220000083_r37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0010-9"},{"key":"S2633289220000083_r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2012.12.002"},{"key":"S2633289220000083_r38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"S2633289220000083_r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.058"},{"key":"S2633289220000083_r20","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70343-8"},{"key":"S2633289220000083_r24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2179-y"},{"key":"S2633289220000083_r21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209548200"},{"key":"S2633289220000083_r13","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2017.0179"},{"key":"S2633289220000083_r18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.21.12090-12095.2004"},{"key":"S2633289220000083_r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104742"},{"key":"S2633289220000083_r22","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3546070"},{"key":"S2633289220000083_r27","unstructured":"UNAIDS (2020) HVTN 702 Clinical Trial of an HIV Vaccine Stopped. Available at https:\/\/www.unaids.org\/en\/resources\/presscentre\/pressreleaseandstatementarchive\/2020\/february\/20200204_vaccine (accessed 04 February 2020)."},{"key":"S2633289220000083_r5","unstructured":"Dalgleish, AG (2020) Is Britain's coronavirus response bogged down in bureaucracy? The Spectator, 28 April 2020. Available at https:\/\/www.spectator.co.uk\/article\/Is-Britain-s-coronavirus-response-bogged-down-in-bureaucracy#(accessed 28 April 2020)."},{"key":"S2633289220000083_r29","unstructured":"Uniprot \u2013 P59594. Spike Glycoprotein, Human SARS Coronavirus (SARS-CoV) (Severe Acute Respiratory Syndrome Coronavirus). (accessed 23 April 2003)."},{"key":"S2633289220000083_r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2011.03.011"},{"key":"S2633289220000083_r10","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-0369"},{"key":"S2633289220000083_r16","article-title":"COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism","author":"Liu","year":"2020","journal-title":"ChemRxiv Preprint."},{"key":"S2633289220000083_r9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6072-3"},{"key":"S2633289220000083_r25","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr363"},{"key":"S2633289220000083_r17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30251-8"},{"key":"S2633289220000083_r7","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.342"},{"key":"S2633289220000083_r8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis342"},{"key":"S2633289220000083_r32","unstructured":"Uniprot \u2013 Q9NNX6. CD209. Available at https:\/\/www.uniprot.org\/uniprot\/Q9NNX6 (accessed 13 April 2004)."},{"key":"S2633289220000083_r34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C300520200"},{"key":"S2633289220000083_r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2009.03.059"},{"key":"S2633289220000083_r6","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1602-8"}],"container-title":["QRB Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2633289220000083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T08:55:56Z","timestamp":1651654556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2633289220000083\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":38,"alternative-id":["S2633289220000083"],"URL":"https:\/\/doi.org\/10.1017\/qrd.2020.8","relation":{"has-review":[{"id-type":"doi","id":"10.1017\/qrd.2020.8.pr4","asserted-by":"object"},{"id-type":"doi","id":"10.1017\/qrd.2020.8.pr3","asserted-by":"object"},{"id-type":"doi","id":"10.1017\/qrd.2020.8.pr2","asserted-by":"object"},{"id-type":"doi","id":"10.1017\/qrd.2020.8.pr1","asserted-by":"object"}]},"ISSN":["2633-2892"],"issn-type":[{"value":"2633-2892","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"article-number":"e6"}}